Weekly Doxorubicin Increases Coronary Arteriolar Wall and Adventitial Thickness

Eckman, Delrae M.; Stacey, R. Brandon; Rowe, Robert; D′Agostino Jr, Ralph; Kock, Nancy D.; Sane, David C.; Torti, Frank M.; Yeboah, Joseph; Workman, Susan; Lane, Kimberly S.; Hundley, W. Gregory
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Doxorubicin (DOX) is associated with premature cardiovascular events including myocardial infarction. This study was performed to determine if the weekly administration of DOX influenced coronary arteriolar medial and/or adventitial wall thickening. Methods: Thirty-two male Sprague-Dawley rats aged 25.1± 2.4 weeks were randomly divided into three groups and received weekly intraperitoneal injections of normal saline (saline, n = 7), or low (1.5 mg/kg to 1.75 mg/kg, n = 14) or high (2.5 mg/kg, n = 11) doses of DOX. The animals were treated for 2–12 weeks, and euthanized at pre-specified intervals (2, 4, 7, or 10+ weeks) to obtain histopathologic assessments of coronary arteriolar lumen diameter, medial wall thickness, adventitial wall thickness, and total wall thickness (medial thickness + adventitial thickness). Results: Lumen diameter was similar across all groups (saline: 315±34 µm, low DOX: 286±24 µm, high DOX: 242±27 µm; p = 0.22). In comparison to animals receiving weekly saline, animals receiving weekly injections of 2.5 mg/kg of DOX experienced an increase in medial (23±2µm vs. 13±3µm; p = 0.005), and total wall thickness (51±4µm vs. 36±5µm; p = 0.022), respectively. These increases, as well as adventitial thickening became more prominent after normalizing for lumen diameter (p<0.05 to p<0.001) and after adjusting for age, weight, and total cumulative DOX dose (p = 0.02 to p = 0.01). Animals receiving low dose DOX trended toward increases in adventitial and total wall thickness after normalization to lumen diameter and accounting for age, weight, and total cumulative DOX dose (p = 0.06 and 0.09, respectively). Conclusion: In conclusion, these data demonstrate that weekly treatment of rats with higher doses of DOX increases coronary arteriolar medial, adventitial, and total wall thickness. Future studies are warranted to determine if DOX related coronary arteriolar effects are reversible or preventable, exacerbate the known cardiomyopathic effects of DOX, influence altered resting or stress-induced myocardial perfusion, or contribute to the occurrence of myocardial infarction.


Related Articles

  • A Metabolomic Study of Rats with Doxorubicin-Induced Cardiomyopathy and Shengmai Injection Treatment. Chen, Yu; Tang, Yong; Zhang, Ya-Chen; Huang, Xiao-Hong; Xie, Yu-Quan; Xiang, Yin // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Doxorubicin-induced cardiomyopathy (DOX-CM) is a severe complication of doxorubicin (DOX) chemotherapy. Characterized by cumulative and irreversible myocardial damage, its pathogenesis has not been fully elucidated. Shengmai Injection (SMI), a Traditional Chinese Medicine, may alleviate...

  • First aldosterone-blocker approved for CHF.  // Drug Topics;10/20/2003, Vol. 147 Issue 20, p8 

    Focuses on the U.S. Food and Drug Administration's approval of an aldosterone-blocker for the congestive heart failure patients following an acute myocardial infarction.

  • COMMENTARY. Prabhakar, Manu; Massel, David // Evidence Based Medicine;Sep2003, p146 

    The author reflects on the advantage of using adjunctive treatment with eplerenone for patients with congestive heart failure (CHF) and acute myocardial infarction (MI).

  • Promising results observed for bioresorbable vascular scaffold in STEMI.  // Cardiology Today;Apr2014, Vol. 17 Issue 4, p50 

    The article reports on the efficacy of bioresorbable vascular scaffold implantation in patients who underwent percutaneous coronary intervention (PCI) for acute ST segment elevation myocardial infarction (STEMI), which was concluded by the multicenter Prague 19 study that was participated by 41...

  • Cardiovascular disease. Gore, Joel M.; Dalen, James E. // JAMA: Journal of the American Medical Association;06/18/97, Vol. 277 Issue 23, p1845 

    Reports on scientific advances in the treatment of cardiovascular disease. Thrombin inhibitor called hirudin which may improve outcome following myocardial infarction; Appropriate therapeutic range for warfarin therapy in patients with atrial fibrillation; Questionable effectiveness of...

  • Pharmacologic Therapy That Simulates Conditioning for Cardiac Ischemic/Reperfusion Injury. Sivaraman, Vivek; Yellon, Derek M. // Journal of Cardiovascular Pharmacology & Therapeutics;Jan2014, Vol. 19 Issue 1, p83 

    Cardiovascular disease remains a leading cause of deaths due to noncommunicable diseases, of which ischemic heart disease forms a large percentage. The main therapeutic strategy to treat ischemic heart disease is reperfusion that could either be medical or surgical. However, reperfusion...

  • Eye on the Literature.  // Formulary;Dec2002, Vol. 37 Issue 12, p624 

    Outlines research on drugs from various publications compiled as of December 2002. Impact of ramipril on outcome of patients with myocardial infarction; Sex-based differences in the effect of digoxin for treatment of heart failure; Aspirin therapy after bypass surgery.

  • AHRQ study finds drop in heart disease problems.  // Hospital Peer Review;Mar2014, Vol. 39 Issue 3, p35 

    The article discusses a study which found that patients treated for heart attacks and heart failure are less likely to have adverse events while patients with pneumonia or recovering from surgery did not have similar declines.

  • The ABCs of Treating Congestive Heart Failure.  // American Family Physician;9/15/2001, Vol. 64 Issue 6, p936 

    Editorial. Introduces an article which summarized guidelines for treating congestive heart failure caused by systolic dysfunction, which appeared on the September 15, 2001 issue of `American Family Physician.'


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics